Aileron Therapeutics Inc.

0.3969-0.0219-5.23%Vol 348.97K1Y Perf -69.65%
Jun 24th, 2022 16:00 DELAYED
BID0.3900 ASK0.4497
Open0.4062 Previous Close0.4188
Pre-Market- After-Market-
 - -  - -%
Target Price
2.00 
Analyst Rating
Strong Buy 1.00
Potential %
403.91 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
7.12 
Earnings Rating
Neutral
Market Cap36.05M 
Earnings Date
10th Aug 2022
Alpha-0.03 Standard Deviation0.37
Beta2.48 

Today's Price Range

0.39690.4500

52W Range

0.32001.40

5 Year PE Ratio Range

-4.60-0.9000

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-5.05%
1 Month
-3.20%
3 Months
-31.28%
6 Months
-30.37%
1 Year
-69.65%
3 Years
-47.78%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALRN0.3969-0.0219-5.23
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.08-0.09-12.50
Q04 2021--0.08-
Q03 2021-0.07-0.070.00
Q02 2021-0.07-0.0614.29
Q01 2021-0.06-0.08-33.33
Q04 2020-0.11-0.12-9.09
Q03 2020-0.10-0.13-30.00
Q02 2020-0.16-0.1412.50
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.09--
9/2022 QR-0.10--
12/2022 FY-0.38--
12/2023 FY-0.38--
Next Report Date10th Aug 2022
Estimated EPS Next Report-0.09
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume348.97K
Shares Outstanding90.82K
Shares Float71.15M
Trades Count563
Dollar Volume148.46K
Avg. Volume278.36K
Avg. Weekly Volume308.82K
Avg. Monthly Volume168.49K
Avg. Quarterly Volume357.77K

Aileron Therapeutics Inc. (NASDAQ: ALRN) stock closed at 0.3969 per share at the end of the most recent trading day (a -5.23% change compared to the prior day closing price) with a volume of 348.97K shares and market capitalization of 36.05M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 13 people. Aileron Therapeutics Inc. CEO is Manuel C. Alves Aivado.

The one-year performance of Aileron Therapeutics Inc. stock is -69.65%, while year-to-date (YTD) performance is -29.49%. ALRN stock has a five-year performance of %. Its 52-week range is between 0.32 and 1.4, which gives ALRN stock a 52-week price range ratio of 7.12%

Aileron Therapeutics Inc. currently has a PE ratio of -1.40, a price-to-book (PB) ratio of 1.05, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -54.50%, a ROC of -56.20% and a ROE of -58.68%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Aileron Therapeutics Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. Aileron Therapeutics Inc.’s next earnings report date is 10th Aug 2022.

The consensus rating of Wall Street analysts for Aileron Therapeutics Inc. is Strong Buy (1), with a target price of $2, which is +403.91% compared to the current price. The earnings rating for Aileron Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aileron Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aileron Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 28.41, ATR14 : 0.04, CCI20 : -20.54, Chaikin Money Flow : -0.26, MACD : -0.01, Money Flow Index : 48.04, ROC : -8.40, RSI : 44.50, STOCH (14,3) : 26.89, STOCH RSI : 0.45, UO : 35.06, Williams %R : -73.11), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aileron Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
2 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aileron Therapeutics Inc.

Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing and commercializing a novel class of therapeutics called stapled peptides. The company's lead product candidate, ALRN-6924, targets the tumor suppressor p53 for the treatment of a wide variety of cancers.

CEO: Manuel C. Alves Aivado

Telephone: +1 617 995-0900

Address: 490 Arsenal Way, Watertown 02472, MA, US

Number of employees: 13

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

59%41%

Bearish Bullish

64%36%

News

Stocktwits